The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 136, No 12, 1658-1668.
© 2005 American Dental Association

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MIGLIORATI, C. A.
Right arrow Articles by WOO, S.-B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MIGLIORATI, C. A.
Right arrow Articles by WOO, S.-B.
Related Collections
Right arrow Infection Control

COVER STORY

JADA Continuing Education

Managing the care of patients with bisphosphonate-associated osteonecrosis

An American Academy of Oral Medicine position paper



CESAR A. MIGLIORATI, D.D.S., M.S., Ph.D., JEFFREY CASIGLIA, D.M.D., JOEL EPSTEIN, D.M.D., M.S.D., F.R.C.D.(C.), PETER L. JACOBSEN, Ph.D., D.D.S., MICHAEL A. SIEGEL, D.D.S., M.S. and SOOK-BIN WOO, D.M.D.

Background. This position paper addresses the prevention of bisphosphonate-associated osteonecrosis (BON) and the management of care of patients with cancer and/or osteoporosis who are receiving bisphosphonates and who have BON or are at risk of developing it.

Methods. The authors reviewed the literature available on this newly described oral complication. Information of interest included bisphosphonates, the medications associated with this oral complication; the patient population at risk of developing BON and the diseases being treated with this class of medications; the clinical presentation of the oral lesions; guidelines for managing the care of patients who develop BON; the prevention of this complication based on current knowledge; and recommendations for routine dental treatment of patients receiving bisphosphonates.

Results. There is strong evidence that bisphosphonate therapy is the common link in patients with BON. The pathobiological mechanism leading to BON may have to do with the inhibition of bone remodeling and decreased intraosseous blood flow caused by bisphosphonates. People at risk include patients with multiple myeloma and patients with cancer metastatic to bone who are receiving intravenous bisphosphonates, as well as patients taking bisphosphonates for osteoporosis. The risk of developing complications appears to increase with time of use of the medication. There are no guidelines based on evidence, and the clinical management of the oral complication is based on expert opinion.

Conclusion. Prevention of BON is the best approach to management of this complication. Existing protocols to manage the care of patients who will receive radiation therapy or chemotherapy may be used until specific guidelines for BON are developed.

Key Words: Osteonecrosis; bisphosphonates; jaw; cancer metastasis; skeletal metastasis; oral complication; osteoporosis




This article has been cited by other articles:


Home page
Ann OncolHome page
F. Jadu, L. Lee, M. Pharoah, D. Reece, and L. Wang
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
Ann. Onc., December 1, 2007; 18(12): 2015 - 2019.
[Abstract] [Full Text] [PDF]


Home page
J. Dent. Res.Home page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
J. Dent. Res., November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Khamaisi, E. Regev, N. Yarom, B. Avni, E. Leitersdorf, I. Raz, and S. Elad
Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1172 - 1175.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard
Bisphosphonate-Induced Osteonecrosis of the Jaw
Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
A. Grey and T. Cundy
Bisphosphonates and osteonecrosis of the jaw.
Ann Intern Med, November 21, 2006; 145(10): 791 - 791.
[Full Text] [PDF]


Home page
IBMS BoneKEyHome page
A. Boyde
Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions
IBMS BoneKEy, September 1, 2006; 3(9): 19 - 23.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2005 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.